AstraZeneca, Merck herald PhIII prostate cancer win for Lynparza — overtaking Clovis, J&J in PARP race

The case for expanding Lynparza’s use just got stronger as AstraZeneca and Merck claim a late-stage success in extending the time prostate cancer patients live without progressing compared to standard of care.